NCT05128734: Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Chemotherapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients that have not had at least one line of chemotherapy (anthracyclines & taxanes) in the context of metastatic disease; Prior treatment with Temodar/temozolomide or Lynparza/olaparib; Patients with bone-only metastases; Patients with untreated active progressive CNS metastases – see trial for details; Patients with known BRCA1 or BRCA2 germline hereditary mutation(s)

Comments are closed.

Up ↑